In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Genta, Aventis sign $480mm antisense deal; ended

Executive Summary

In the largest biotech alliance announced so far this year, Genta (cancer therapeutics) and Aventis will co-develop Genta's lead program Genasense (oblimersen sodium), an antisense product that is in several Phase III trials in combination with chemotherapy drugs to treat solid tumors and cancers of the blood.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Equity
    • Co-Promotion
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register